KEGG DRUG: Ufrenmeran

DRUG: Ufrenmeran

Entry

D12610                      Drug

Name

Ufrenmeran (JAN/INN);
Tegrenmeran (JAN);
Bemremeran (JAN);
MAFB-7256a;
Daichirona (TN)

Class

Antiviral
DG03172 COVID-19 vaccine

Remark

Therapeutic category:

6313

ATC code:

J07BN01

Product:

D12610<JP>

Efficacy

Active immunization (SARS-CoV-2)

Target

SARS-CoV-2 spike glycoprotein [KO:K24152]

Pathway

ko03230

Viral genome structure

ko03262

Virion - Coronavirus

ko05171

Coronavirus disease - COVID-19

Network

nt06171

SARS coronavirus 2 (SARS-CoV-2)

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
  J07 VACCINES
   J07B VIRAL VACCINES
    J07BN Covid-19 vaccines
     J07BN01 Covid-19, RNA-based vaccine
      D12610  Ufrenmeran (JAN/INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
6  Agents against pathologic organisms and parasites
  63  Biological preparations
   631  Vaccines
    6313  Viral vaccines
     D12610  Ufrenmeran (JAN/INN); Tegrenmeran (JAN); Bemremeran (JAN)
Drug groups [BR:br08330]
Antiviral
  DG03172  COVID-19 vaccine
   D12610  Ufrenmeran
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D12610

Other DBs

CAS:	2749556-96-3

PubChem:

497621023

LinkDB

» Japanese version » Back

DBGET integrated database retrieval system